arrow
R

Rosa Ayala

hospital universitario 12 de octubre
H指数:29
被引数:3,237

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Venetoclax-based therapy versus hypomethylating agents alone in unfit patients with newly diagnosed acute myeloid leukemia: a real-world study from the PETHEMA registry

维奈克拉为基础的治疗与单用去甲基化药物在初诊急性髓系白血病不适宜患者中的比较:一项来自PETHEMA登记研究的真实世界研究

Leukemia
IF13.4
2026-10-060
OA
Real-World Outcomes of Midostaurin Plus Intensive Chemotherapy in FLT3-Mutated AML: The PETHRATIFY Study
2026-09-010
OAAI
Survival outcomes and treatment patterns in myelofibrosis in the JAK inhibitor era

JAK抑制剂时代骨髓纤维化的生存结局与治疗模式

2026-08-210
PREAI
Mutational profile and cardiovascular risk factors impact prognosis in triple-negative essential thrombocythemia

突变谱和心血管风险因素对三阴性原发性血小板增多症预后的影响

Leukemia
IF13.4
2026-07-130
OAAI
Impact of molecular profiling in patients with acute myeloid leukemia undergoing allogeneic transplantation in first remission: a study by the PETHEMA group

急性髓系白血病患者在首次缓解期接受 allo 移植时分子分型的临床影响:PETHEMA 小组的研究

2026-05-070
PRE
Interlaboratory cross validation of acute myeloid leukemia fusion genes and mutational targets detected by PCR: Performance of PETHEMA central laboratories

实验室间交叉验证由PCR检测到的急性髓系白血病融合基因和突变靶点:PETHEMA中心实验室的表现

2025-12-010
PRE
OPTICAL GENOME MAPPING IN MYELOFIBROSIS: ENHANCING PROGNOSTIC ACCURACY THROUGH HIGH-RESOLUTION GENOMIC PROFILING.

光学基因组作图在骨髓纤维化中的应用:通过高分辨率基因组分析提高预后准确性。

2025-10-300
OAAI
Long-term benefits of autologous stem cell transplantation versus intensive chemotherapy consolidation for acute myeloid leukemia patients: A propensity score matching analysis from the PETHEMA AML registry

自体干细胞移植与强化疗巩固治疗急性髓系白血病患者的长期获益:一项来自PETHEMA AML登记研究的倾向性评分匹配分析

Leukemia
IF13.4
2025-09-010
OAAI
Exploratory Study to Evaluate the Impact of Interim PET/CT Assessment in First-Line Follicular Lymphoma

探索性研究:评估首次滤泡性淋巴瘤治疗中中期PET/CT评估的影响

CANCERS
IF4.4
2025-03-210
OA
Impact of somatic gene mutations on the risk of thrombosis in myelofibrosis
LEUKEMIA
IF13.4
2024-08-300
PRE
Evolving patterns and clinical outcome of genetic studies performed at diagnosis in acute myeloid leukemia patients: Real life data from the PETHEMA Registry
CANCER
IF5.1
2024-06-191
PRE
Do NPM1 and FLT3-ITD mutations modify prognosis in patients treated with non-intensive regimens?
2024-06-170
PRE
Validation of mutated CEBPA bZIP as a distinct prognosis entity in acute myeloid leukemia: a study by the Spanish PETHEMA registry
2024-04-180
OAAI
Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA (vol 12, 13057, 2022)
2024-03-280
OAAI
Integrating AIPSS-MF and molecular predictors: A comparative analysis of prognostic models for myelofibrosis
2024-03-201
OAAI
The prognostic impact of non-driver gene mutations and variant allele frequency in primary myelofibrosis
2024-01-303
OAAI
Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients
2024-01-100
OAAI